1. Home
  2. KPLT vs XGN Comparison

KPLT vs XGN Comparison

Compare KPLT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Katapult Holdings Inc.

KPLT

Katapult Holdings Inc.

HOLD

Current Price

$6.84

Market Cap

52.2M

ML Signal

HOLD

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$5.99

Market Cap

138.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPLT
XGN
Founded
2012
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.2M
138.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
KPLT
XGN
Price
$6.84
$5.99
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$10.00
$13.67
AVG Volume (30 Days)
1.1M
259.1K
Earning Date
11-12-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$280,839,000.00
$63,599,000.00
Revenue This Year
$21.42
$21.76
Revenue Next Year
$15.48
$15.63
P/E Ratio
N/A
N/A
Revenue Growth
16.15
14.08
52 Week Low
$5.50
$2.67
52 Week High
$24.34
$12.23

Technical Indicators

Market Signals
Indicator
KPLT
XGN
Relative Strength Index (RSI) 45.74 24.18
Support Level $6.50 $5.93
Resistance Level $6.80 $6.34
Average True Range (ATR) 0.57 0.34
MACD 0.20 0.02
Stochastic Oscillator 20.90 9.73

Price Performance

Historical Comparison
KPLT
XGN

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: